OTCMKTS:IMVIQ

IMV (IMVIQ) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
1 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IMVIQ stock logo

About IMV Stock (OTCMKTS:IMVIQ)

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

IMVIQ Stock News Headlines

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.
Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.
Best Games Like The Sims 4
Best Games Like The Sims 4
IMVIQ - IMV Inc.
See More Headlines
Receive IMVIQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IMV and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
5/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:IMVIQ
Fax
N/A
Employees
63
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$330,000.00
Book Value
($0.69) per share

Miscellaneous

Free Float
11,673,000
Optionable
Not Optionable
Beta
0.71
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Andrew Hall M.Sc.
    CEO & Director
  • Ms. Brittany Davison C.A. (Age 34)
    CPA, Chief Accounting Officer, Corporate Secretary & Director
    Comp: $207.9k
  • Dr. Jeremy R. Graff Ph.D. (Age 53)
    Chief Scientific Officer
    Comp: $558.1k
  • Delphine Davan
    Senior Director of Communications & Investor Relations
  • Mr. Stephan Fiset M.B.A.
    M.Sc., Vice President of Clinical Research

IMVIQ Stock Analysis - Frequently Asked Questions

How do I buy shares of IMV?

Shares of IMVIQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:IMVIQ) was last updated on 5/5/2024 by MarketBeat.com Staff

From Our Partners